Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergopharma GmbH & Co. KG
• Treatments: Glycerol; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 4 - <12 years (at the time of inclusion)

• Positive SPT

• Positive EAST

• Positive CPT

Exclusion Criteria:

• Serious chronic diseases

• Other perennial allergies